Wat is de prijs voor Medigene AG (MDG1)

Het prijs van Medigene AG (MDG1) is $0.14942078

Wat is de marktkapitalisatie voor Medigene AG (MDG1)

Marktkapitalisatie voorMedigene AG (MDG1) is $3.86M

Medigene AG (MDG1) Uitstaande Aandelen

Medigene AG is a German biotechnology company primarily focused on innovating T cell immunotherapies to treat various cancers. Their developmental pipeline includes personalized T cell therapies, particularly T cell receptor-modified T cells, which are progressing through clinical stages to tackle significant unmet medical requirements. Additionally, the firm researches dendritic cell vaccines and T cell-specific monoclonal antibodies. Outside of its oncology efforts, Medigene is actively engaged in developing and bringing to market RhuDex for uses within hepatology and gastroenterology. A key strategic alliance exists with 2seventy bio, Inc., centered on advancing T cell receptors. The company also maintains research collaborations with the Université de Montréal and Cytovant Sciences Co. Ltd., investigating new cancer antigens for immunotherapy applications. Medigene's global presence encompasses operations across Europe, the United States, Asia, and various other international territories. Founded in 1994, the company's headquarters are located in Munich, Germany.

Jaar	Uitstaande aandelen	Wijzigen
2026 (TTM)	12.93M	5.30%
2023	12.28M	-5.04%
2022	12.93M	0.00%
2021	12.93M	0.00%
2020	12.93M	0.01%
2019	12.93M	-48.12%
2018	24.93M	10.08%
2017	22.64M	7.76%
2016	21.01M	25.00%
2015	16.81M	37.65%
2014	12.21M	27.07%
2013	9.61M	3.65%
2012	9.27M	89.92%
2011	4.88M	1.42%
2010	4.81M	6.81%
2009	4.51M	0.66%
2008	4.48M	7.82%
2007	4.15M	40.74%
2006	2.95M	20.75%
2005	2.44M	32.61%
2004	1.84M	0.00%

Jaar

Uitstaande aandelen

Wijzigen

2026 (TTM)

12.93M

5.30%

2023

12.28M

-5.04%

2022

12.93M

0.00%

2021

12.93M

0.00%

2020

12.93M

0.01%

2019

12.93M

-48.12%

2018

24.93M

10.08%

2017

22.64M

7.76%

2016

21.01M

25.00%

2015

16.81M

37.65%

2014

12.21M

27.07%

2013

9.61M

3.65%

2012

9.27M

89.92%

2011

4.88M

1.42%

2010

4.81M

6.81%

2009

4.51M

0.66%

2008

4.48M

7.82%

2007

4.15M

40.74%

2006

2.95M

20.75%

2005

2.44M

32.61%

2004

1.84M

0.00%

Bedrijf	Uitstaande aandelen	Verschil	Land
Vertex Pharmaceuticals Incorporated VRTX.US	253.90M	1,863.24%	US
Argenx SE ARGX.US	62.19M	380.84%	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	0.00	-100.00%	BE

Bedrijf

Uitstaande aandelen

Verschil

Land